China Biotech Services Holdings (HKSE:08037) Piotroski F-Score: 4 (As of Jul. 25, 2026) — 20% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08037 China Biotech Services Holdings Ltd HKSE:08037
19 GF Score
Price HK$0.64
GF Value HK$0.27
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is China Biotech Services Holdings Piotroski F-Score?

China Biotech Services Holdings HKSE:08037 -1.54% 19 Piotroski F-Score is 4 as of Jul. 25, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks worse than 52.63% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Biotech Services Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for China Biotech Services Holdings's Piotroski F-Score or its related term are showing as below:

HKSE:08037' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of China Biotech Services Holdings was 8. The lowest was 1. And the median was 5.

China Biotech Services Holdings  (HKSE:08037) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


China Biotech Services Holdings Piotroski F-Score Related Terms


China Biotech Services Holdings Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for China Biotech Services Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Biotech Services Holdings Piotroski F-Score Chart

China Biotech Services Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 5.00 1.00 4.00

China Biotech Services Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 0.00 1.00 0.00 4.00

HKSE:08037 vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, China Biotech Services Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Biotech Services Holdings Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where China Biotech Services Holdings's Piotroski F-Score falls into.


HKSE:08037
19GF Score
China Biotech Services Holdings Ltd HKSE:08037
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was HK$-68.78 Mil.
Cash Flow from Operations was HK$-45.98 Mil.
Revenue was HK$73.50 Mil.
Gross Profit was HK$7.73 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (529.955 + 702.575) / 2 = HK$616.265 Mil.
Total Assets at the begining of this year (Dec24) was HK$529.96 Mil.
Long-Term Debt & Capital Lease Obligation was HK$147.74 Mil.
Total Current Assets was HK$79.69 Mil.
Total Current Liabilities was HK$345.76 Mil.
Net Income was HK$-198.15 Mil.

Revenue was HK$70.51 Mil.
Gross Profit was HK$-4.94 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (662.362 + 529.955) / 2 = HK$596.1585 Mil.
Total Assets at the begining of last year (Dec23) was HK$662.36 Mil.
Long-Term Debt & Capital Lease Obligation was HK$43.43 Mil.
Total Current Assets was HK$63.10 Mil.
Total Current Liabilities was HK$192.61 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Biotech Services Holdings's current Net Income (TTM) was -68.78. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

China Biotech Services Holdings's current Cash Flow from Operations (TTM) was -45.98. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-68.778/529.955
=-0.12978083

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-198.146/662.362
=-0.29915062

China Biotech Services Holdings's return on assets of this year was -0.12978083. China Biotech Services Holdings's return on assets of last year was -0.29915062. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

China Biotech Services Holdings's current Net Income (TTM) was -68.78. China Biotech Services Holdings's current Cash Flow from Operations (TTM) was -45.98. ==> -45.98 > -68.78 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=147.743/616.265
=0.2397394

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=43.428/596.1585
=0.0728464

China Biotech Services Holdings's gearing of this year was 0.2397394. China Biotech Services Holdings's gearing of last year was 0.0728464. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=79.689/345.758
=0.23047623

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=63.095/192.614
=0.32757224

China Biotech Services Holdings's current ratio of this year was 0.23047623. China Biotech Services Holdings's current ratio of last year was 0.32757224. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

China Biotech Services Holdings's number of shares in issue this year was 975.731. China Biotech Services Holdings's number of shares in issue last year was 968.491. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7.726/73.503
=0.10511136

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-4.94/70.509
=-0.07006198

China Biotech Services Holdings's gross margin of this year was 0.10511136. China Biotech Services Holdings's gross margin of last year was -0.07006198. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=73.503/529.955
=0.13869668

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=70.509/662.362
=0.10645085

China Biotech Services Holdings's asset turnover of this year was 0.13869668. China Biotech Services Holdings's asset turnover of last year was 0.10645085. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

China Biotech Services Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
China Biotech Services Holdings (HKSE:08037) has a Piotroski F-Score of 4 as of Jul. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Biotech Services Holdings and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, China Biotech Services Holdings' Piotroski F-Score has ranged from 1.00 to 8.00. According to the industry distribution chart, China Biotech Services Holdings ranks #110 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is China Biotech Services Holdings' Piotroski F-Score too high?
China Biotech Services Holdings' current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 8.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. China Biotech Services Holdings' value of 4 is 20% below this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #110 out of 209 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #110 out of 209 companies for Piotroski F-Score. This places China Biotech Services Holdings in the lower half of its industry. The industry median Piotroski F-Score is 5.00. China Biotech Services Holdings' value of 4 is 20% below this benchmark. Historically, China Biotech Services Holdings' own Piotroski F-Score has ranged from 1.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, China Biotech Services Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Piotroski F-Score is 4 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?

Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued. The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27. GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.

Key valuation signals for HKSE:08037:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
  • GF Score™: 19/100 with 6 warning signs
  • Industry Position: 20% below the Medical Diagnostics & Research median (#110 of 209)

No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Biotech Services Holdings Business Description

Address 255-257 Gloucester Road, Suites 1904-05A, 19th Floor, Sino Plaza, Causeway Bay, Hong Kong, HKG
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score

Get the complete analysis for HKSE:08037

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.64
Price
HK$0.27
GF Value